Other growth factor receptors

Other growth factor receptors is a collective term used in pharmacological and clinical contexts to describe a diverse array of receptors that do not belong to the primary, most extensively characterized families like the Epidermal Growth Factor Receptor (EGFR) or Vascular Endothelial Growth Factor Receptor (VEGFR) groups (Source: NIH, PubMed). These receptors, predominantly belonging to the receptor tyrosine kinase (RTK) superfamily, are essential for transducing extracellular signals that regulate cell growth, metabolism, and tissue repair (Source: UniProt). In many cancers, these other receptors—such as MET, KIT, and AXL—are frequently implicated in oncogenesis and the development of resistance to targeted therapies through bypass signaling mechanisms (Source: PubMed, PMC). Drugs targeting these receptors often include multi-kinase inhibitors like sunitinib and sorafenib, which provide therapeutic benefit by blocking multiple signaling pathways simultaneously (Source: PubChem). However, the broad activity of these agents often leads to significant safety concerns, including systemic toxicities like hypertension and gastrointestinal issues (Source: StatPearls). Consequently, identifying specific biomarkers for these miscellaneous receptors is crucial for optimizing patient selection and improving clinical outcomes (Source: NIH).

Other names

Miscellaneous growth factor receptorsNon-canonical growth factor receptorsAdditional growth factor receptorsBypass growth factor receptorsMiscellaneous receptor tyrosine kinases

Inhibition of receptor tyrosine kinase activity, competitive ATP binding, or ligand-receptor interaction blockade.